AstraZeneca’s Imfinzi Gets Pass From FDA Advisors But Future Perioperative Drugs Don’t

 
• By Sarah Karlin-Smith
  
black and white image of doctor with floating lungs above doctor's hands.
The ODAC discussion may have saved AstraZeneca's Imfinizi from a complete response letter. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers